Leprosy 3 (LPRS3)

Categories: Endocrine diseases, Eye diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Leprosy 3

MalaCards integrated aliases for Leprosy 3:

Name: Leprosy 3 56 29 6
Leprosy 56 12 74 25 58 43 15 17 71
Leprosy, Susceptibility to 56 13
Infection Due to Mycobacterium Leprae 25
Leprosy, Susceptibility to, 3 56
Hansen's Disease 25
Leprosy, Type 3 39
Hansen Disease 25
Lprs3 56


Orphanet epidemiological data:

Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Worldwide); Age of onset: All ages; Age of death: any age;


autosomal dominant

see for a discussion on leprosy susceptibility


Orphanet: 58  
Rare neurological diseases
Rare infertility disorders
Rare infectious diseases

External Ids:

Disease Ontology 12 DOID:1024
OMIM 56 246300
ICD9CM 34 030 030.9
MeSH 43 D007918
NCIt 49 C84824
SNOMED-CT 67 81004002
ICD10 32 A30 A30.9
MESH via Orphanet 44 D007918
UMLS via Orphanet 72 C0023343
Orphanet 58 ORPHA548
MedGen 41 C1968668
SNOMED-CT via HPO 68 258211005 263681008
UMLS 71 C0023343

Summaries for Leprosy 3

Genetics Home Reference : 25 Leprosy, also called Hansen disease, is a disorder known since ancient times. It is caused by bacteria called Mycobacterium leprae and is contagious, which means that it can be passed from person to person. It is usually contracted by breathing airborne droplets from affected individuals' coughs and sneezes, or by coming into contact with their nasal fluids. However, it is not highly transmissible, and approximately 95 percent of individuals who are exposed to Mycobacterium leprae never develop leprosy. The infection can be contracted at any age, and signs and symptoms can take anywhere from several months to 20 years to appear. Mycobacterium leprae Mycobacterium leprae Leprosy affects the skin and the peripheral nerves, which connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, and heat. Most affected individuals have areas of skin damage (cutaneous lesions) and problems with nerve function (peripheral neuropathy); however, the severity and extent of the problems vary widely. Leprosy occurs on a spectrum, in which the most severe form is called multibacillary or lepromatous, and the least severe form is called paucibacillary or tuberculoid. Patterns of signs and symptoms intermediate between these forms are sometimes called borderline forms. Multibacillary leprosy usually involves a large number of cutaneous lesions, including both surface damage and lumps under the skin (nodules). The moist tissues that line body openings such as the eyelids and the inside of the nose and mouth (mucous membranes) can also be affected, which can lead to vision loss, destruction of nasal tissue, or impaired speech. Some affected individuals have damage to internal organs and tissues. The nerve damage that occurs in multibacillary leprosy often results in a lack of sensation in the hands and feet. Repeated injuries that go unnoticed and untreated because of this lack of sensation can lead to reabsorption of affected fingers or toes by the body, resulting in the shortening or loss of these digits. Paucibacillary leprosy typically involves a small number of surface lesions on the skin. There is generally loss of sensation in these areas, but the other signs and symptoms that occur in multibacillary leprosy are less likely to develop in this form of the disorder. In any form of leprosy, episodes called reactions can occur, and can lead to further nerve damage. These episodes can include reversal reactions, which involve pain and swelling of the skin lesions and the nerves in the hands and feet. People with the more severe forms of leprosy can develop a type of reaction called erythema nodosum leprosum (ENL). These episodes involve fever and painful skin nodules. In addition, painful, swollen nerves can occur. ENL can also lead to inflammation of the joints, eyes, and the testicles in men. Leprosy has long been stigmatized because of its infectious nature and the disfigurement it can cause. This stigma can cause social and emotional problems for affected individuals. However, modern treatments can prevent leprosy from getting worse and spreading to other people. While the infection is curable, nerve and tissue damage that occurred before treatment is generally permanent.

MalaCards based summary : Leprosy 3, also known as leprosy, is related to borderline leprosy and tuberculoid leprosy, and has symptoms including skin lesions, sensory loss and motor loss. An important gene associated with Leprosy 3 is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Rifampicin and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include superficial peripheral nerves, skin and mucous membranes of the upper respiratory tract, and related phenotypes are abnormality of the immune system and hematopoietic system

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in superficial peripheral nerves, located in skin, located in mucous membranes of the upper respiratory tract, located in anterior chamber of the eyes, or located in testes, has material basis in Mycobacterium leprae, which is transmitted by aerosol spread from infected nasal secretions to exposed nasal and oral mucosa. The infection has symptom skin lesions, has symptom sensory loss, has symptom motor loss and has symptom eye damage.

Wikipedia : 74 Leprosy, also known as Hansen's disease (HD), is a long-term infection by the bacteria Mycobacterium... more...

More information from OMIM: 246300

Related Diseases for Leprosy 3

Diseases in the Leprosy 3 family:

Leprosy 2 Leprosy 1
Leprosy 4 Leprosy 5
Leprosy 6

Diseases related to Leprosy 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1108)
# Related Disease Score Top Affiliating Genes
1 borderline leprosy 35.4 SDHD MLLT1 CD40LG CCDC122
2 tuberculoid leprosy 35.3 SDHD IL2 IL10 IFNG CD4 CCR6
3 indeterminate leprosy 35.2 SLC11A1 SDHD PACRG MLLT1 CD40LG CCDC122
4 buruli ulcer 33.4 SLC11A1 IL10 IFNG
5 neuritis 32.1 TNF IL10 IFNG
6 syphilis 32.0 CD8A CD40LG CD4 CCR6
7 leishmaniasis 31.8 TNF TLR2 SLC11A1 IL2 IL10 IFNG
8 iridocyclitis 31.7 TNF CD40LG CD4
9 allergic hypersensitivity disease 31.7 TNF TLR2 IL2 IL10 IFNG CD4
10 mycobacterium tuberculosis 1 31.6 TNF TLR2 SLC11A1 NOD2 IL10 IFNG
11 uveitis 31.6 TNF NOD2 IL2 IL10 IFNG
12 peripheral nervous system disease 31.5 TNF TLR2 PRKN MLLT1 IL2 IL10
13 keratitis, hereditary 31.5 TNF TLR2 IL10 CD8A CD4 CCR6
14 sarcoidosis 1 31.5 TNF SLC11A1 NOD2 IL2 IFNG CD8A
15 skin disease 31.5 TNF TLR2 IL2 IL10 IFNG CD8A
16 facial paralysis 31.5 CD8A CD40LG CD4
17 cutaneous leishmaniasis 31.5 TNF TLR2 SLC11A1 IL2 IL10 IFNG
18 chronic granulomatous disease 31.4 TNF SLC11A1 LACC1 IFNG CD40LG
19 immune deficiency disease 31.4 TNF IL2 IL10 IFNG CD40LG CD4
20 iritis 31.4 TNF NOD2 CD40LG CD4 CCR6
21 exanthem 31.4 TNF IL2 IL10 CD8A CD40LG CD4
22 autoimmune disease 31.4 TNF SLC11A1 IL2 IL10 IFNG CD40LG
23 arthritis 31.4 TNF TLR2 SLC11A1 NOD2 LACC1 IL10
24 tetanus 31.4 TNF IL2 IL10 IFNG CD40LG
25 tenosynovitis 31.3 TNF NOD2 CD40LG
26 psoriasis 31.3 TNF TLR2 NOD2 IL2 IL10 IFNG
27 filariasis 31.3 TNF TLR2 IL2 IL10 IFNG
28 human immunodeficiency virus type 1 31.3 TNF IL2 IL10 IFNG CD4
29 dermatitis 31.2 TNF TLR2 NOD2 IL2 IL10 IFNG
30 vitiligo-associated multiple autoimmune disease susceptibility 1 31.2 IL2 CD8A CD4 CCR6
31 osteomyelitis 31.2 TNF TLR2 NOD2 IL10 IFNG
32 rheumatic disease 31.2 TNF IL10 IFNG CD40LG CCR6
33 visceral leishmaniasis 31.2 TNF TLR2 SLC11A1 IL2 IL10 IFNG
34 granulomatous dermatitis 31.2 TNF NOD2 CD40LG CD4
35 secondary syphilis 31.2 CD8A CD40LG CD4
36 conjunctivitis 31.1 TNF IL2 IL10 IFNG
37 scleritis 31.1 TNF IFNG CCR6
38 norwegian scabies 31.1 CD8A CD40LG CD4
39 erythema multiforme 31.1 TNF IL2 IFNG
40 proteasome-associated autoinflammatory syndrome 1 31.1 TNF TLR2 IL10 IFNG
41 plague 31.1 TNF TLR2 IL10 CD8A CD4
42 lymphadenitis 31.1 TNF SLC11A1 NOD2 IL10 IFNG CD4
43 periodontitis 31.1 TNF TLR2 IL10 IFNG
44 sporotrichosis 31.1 TNF IL10 IFNG CD40LG CD4
45 mucocutaneous leishmaniasis 31.1 TNF IL2 IL10 IFNG CD8A CD4
46 systemic lupus erythematosus 31.0 TNF TLR2 IL2 IL10 IFNG CD8A
47 lymphopenia 31.0 IL2 IL10 IFNG CCR6
48 pfeiffer syndrome 31.0 IL2 CD8A CD40LG CD4 CCR6
49 poliomyelitis 31.0 TNF IL10 IFNG CD8A CD40LG CD4
50 filarial elephantiasis 31.0 TLR2 IL10 CD4

Comorbidity relations with Leprosy 3 via Phenotypic Disease Network (PDN):

Acute Cystitis

Graphical network of the top 20 diseases related to Leprosy 3:

Diseases related to Leprosy 3

Symptoms & Phenotypes for Leprosy 3

Human phenotypes related to Leprosy 3:

# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 31 HP:0002715

Symptoms via clinical synopsis from OMIM:

susceptibility to infection by mycobacterium leprae causing leprosy

Clinical features from OMIM:



  • skin lesions
  • sensory loss
  • motor loss
  • eye damage

MGI Mouse Phenotypes related to Leprosy 3:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.33 CCR6 CD4 CD40LG CD8A IFNG IL10
2 cellular MP:0005384 10.32 CD4 CD40LG CD8A IFNG IL10 IL2
3 homeostasis/metabolism MP:0005376 10.25 CCR6 CD4 CD40LG IFNG IL10 IL2
4 immune system MP:0005387 10.25 CCR6 CD4 CD40LG CD8A IFNG IL10
5 cardiovascular system MP:0005385 10.22 CCR6 CD40LG IFNG IL10 IL2 LRRK2
6 endocrine/exocrine gland MP:0005379 10.18 CD4 CD40LG CD8A IFNG IL10 IL2
7 mortality/aging MP:0010768 10.17 CD4 CD40LG CD8A IFNG IL10 IL2
8 digestive/alimentary MP:0005381 10.1 CD4 IFNG IL10 IL2 NOD2 SLC11A1
9 integument MP:0010771 10.02 CD4 CD40LG CD8A IFNG IL10 LRRK2
10 nervous system MP:0003631 9.9 CCR6 CD4 CD40LG CD8A IFNG IL10
11 neoplasm MP:0002006 9.86 IFNG IL10 IL2 MLLT1 SDHD SLC11A1
12 no phenotypic analysis MP:0003012 9.5 CD4 IFNG IL10 IL2 LRRK2 PRKN
13 normal MP:0002873 9.32 CCR6 CD4 CD8A IFNG IL10 LRRK2

Drugs & Therapeutics for Leprosy 3

Drugs for Leprosy 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3 Cytochrome P-450 CYP3A Inducers Phase 4
4 Antibiotics, Antitubercular Phase 4
5 Antiparasitic Agents Phase 4
6 Antiprotozoal Agents Phase 4
7 Antimalarials Phase 4
8 Vitamins Phase 4
9 Vaccines Phase 4
10 Anti-Bacterial Agents Phase 4
11 Anti-Infective Agents Phase 4
12 Immunosuppressive Agents Phase 4
13 Angiogenesis Inhibitors Phase 4
14 Immunologic Factors Phase 4
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
Perphenazine Approved Phase 3 58-39-9 4748
Amitriptyline Approved Phase 3 50-48-6 2160
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
Leuprolide Approved, Investigational Phase 3 53714-56-0 3911 657181
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
Infliximab Approved Phase 3 170277-31-3
Clofazimine Approved, Investigational Phase 2, Phase 3 2030-63-9 2794
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
Norgestimate Approved, Investigational Phase 2, Phase 3 35189-28-7 6540478
Linezolid Approved, Investigational Phase 2, Phase 3 165800-03-3 441401
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3 50-28-2 5757
Polyestradiol phosphate Approved Phase 2, Phase 3 28014-46-2
Moxifloxacin Approved, Investigational Phase 2, Phase 3 151096-09-2, 354812-41-2 152946
Ethinyl Estradiol Approved Phase 2, Phase 3 57-63-6 5991
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
36 Tocotrienol Investigational Phase 3 6829-55-6
37 Antipsychotic Agents Phase 3
38 Tranquilizing Agents Phase 3
39 Narcotics Phase 3
40 Psychotropic Drugs Phase 3
41 Analgesics, Opioid Phase 3
42 Analgesics, Non-Narcotic Phase 3
43 Antidepressive Agents Phase 3
44 Analgesics Phase 3
45 Central Nervous System Depressants Phase 3
46 Amitriptyline, perphenazine drug combination Phase 3
47 Adrenergic Agents Phase 3
48 Antidepressive Agents, Tricyclic Phase 3
49 Cyclosporins Phase 2, Phase 3
50 Antifungal Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
3 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
4 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
5 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Recruiting NCT03519568 Phase 4
6 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
7 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Unknown status NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
8 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
9 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
10 Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters Completed NCT00265226 Phase 3
11 Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters Completed NCT00341328 Phase 3
12 Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection) Completed NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
13 A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation Completed NCT00004635 Phase 3 Thalidomide;leuprolide acetate;goserelin
14 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
15 Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home Completed NCT00289497 Phase 2, Phase 3
16 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
17 Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
18 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Not yet recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
19 Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) Not yet recruiting NCT04081077 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine
20 To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus. Unknown status NCT02023411 Phase 2 Teriparatide
21 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
22 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
23 Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00162760 Phase 2 Thalidomide
24 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
25 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
26 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
27 A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas Completed NCT00047879 Phase 2 Thalidomide
28 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
29 Efficacy and Safety of Low Dose Thalidomide in Thalassemia Intermedia Patients of Pakistan Recruiting NCT03651102 Phase 2 Thalidomide Oral Product
30 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
31 Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease Recruiting NCT02968212 Phase 2 Clofazimine
32 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Not yet recruiting NCT03947437 Phase 1, Phase 2
33 A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis. Terminated NCT00469703 Phase 2 Thalidomide
34 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
35 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Terminated NCT03341767 Phase 2 Clofazimine;Placebo
36 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
37 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
38 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
39 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
40 Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses Completed NCT02493283 Phase 1 Dapsone single dose;Dapsone multiple dose
41 A Phase I Study of the Safety and Immunogenicity of BCG (Bacille Calmette-Guerin) Vaccine Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG. Completed NCT00654316 Phase 1
42 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
43 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis. Completed NCT00456183 Phase 1
44 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV Completed NCT00395720 Phase 1
45 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
46 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
47 Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer. Unknown status NCT01751503
48 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437
49 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
50 Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial Completed NCT00860717

Search NIH Clinical Center for Leprosy 3

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cochrane evidence based reviews: leprosy

Genetic Tests for Leprosy 3

Genetic tests related to Leprosy 3:

# Genetic test Affiliating Genes
1 Leprosy 3 29 TLR2

Anatomical Context for Leprosy 3

The Foundational Model of Anatomy Ontology organs/tissues related to Leprosy 3:

Superficial Peripheral Nerves, Skin, Mucous Membranes Of The Upper Respiratory Tract, Anterior Chamber Of The Eyes, Testes

MalaCards organs/tissues related to Leprosy 3:

Skin, Testes, T Cells, Eye, Bone, Liver, Monocytes

Publications for Leprosy 3

Articles related to Leprosy 3:

(show top 50) (show all 20055)
# Title Authors PMID Year
No involvement of non-synonymous TLR2 polymorphisms in Japanese leprosy patients. 61 56 6
19111445 2009
TLR2 Arg677Trp polymorphism in leprosy: revisited. 61 56 6
15726416 2005
Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. 61 56 6
12646604 2003
Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. 61 56 6
11476982 2001
Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. 61 6
19456232 2009
Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. 61 56
18177245 2008
The polymorphism P315L of human toll-like receptor 1 impairs innate immune sensing of microbial cell wall components. 6
17475868 2007
A family of human receptors structurally related to Drosophila Toll. 56
9435236 1998
Clinicodermoscopic study of histoid leprosy: a case series. 61
31769010 2020
A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults. 61
31899025 2020
A distinct double positive IL-17A+/F+ T helper 17 cells induced inflammation leads to IL17 producing neutrophils in Type 1 reaction of leprosy patients. 61
31629113 2020
Erythema Nodosum Leprosum Neutrophil Subset Expressing IL-10R1 Transmigrates into Skin Lesions and Responds to IL-10. 61
32034084 2020
A case of diffuse lepromatous leprosy with Lucio phenomenon. 61
31198950 2020
Scoping review: Community-based programmes with people affected by leprosy. 61
31713954 2020
Hot spots of leprosy in the endemic area of São Luís, Maranhão State, Northeastern Brazil. 61
31501023 2020
Leprosy in the North and Northeast regions of Brazil: an integrated spatiotemporal approach. 61
31713982 2020
Letter to editor in response to the article 'Position statement: LEPROSY: diagnosis, treatment and follow-up'. 61
31505055 2020
The Importance of the Biopsy Technique in the Diagnosis of Histoid Leprosy. 61
31268927 2020
Case Report: Nasal Myiasis in an Elderly Patient with Atrophic Rhinitis and Facial Sequelae of Leprosy. 61
31802737 2020
Nursing in a Community With Leprosy at the Center: A Conversation With Remi Kalnime. 61
32024736 2020
Community health care workers in pursuit of TB: Discourses and dilemmas. 61
31954279 2020
"Buruli ulcer and leprosy, they are intertwined": Patient experiences of integrated case management of skin neglected tropical diseases in Liberia. 61
32023242 2020
Efficacy of Topical Insulin Therapy for Chronic Trophic Ulcers in Patients with Leprosy: A Randomized Interventional Pilot Study. 61
31972587 2020
Sarcoidosis with Cutaneous Perineural Granulomas and Neurological Manifestations: A Potential Mimicker of Leprosy. 61
32022940 2020
Proposing BCG Vaccination for Mycobacterium avium ss. paratuberculosis (MAP) Associated Autoimmune Diseases. 61
32033287 2020
Leprosy in urban space, areas of risk for disability and worsening of this health condition in Foz Do Iguaçu, the border region between Brazil, Paraguay and Argentina. 61
31996183 2020
A Quality of Life Study of Patients with Leprosy Attending the Dermatology OPD of a Tertiary Care Center of Eastern India. 61
32029939 2020
Effectiveness and safety of autologous platelet-rich plasma therapy with total contact casting versus total contact casting alone in treatment of trophic ulcer in leprosy: An observer-blind, randomized controlled trial. 61
31997794 2020
Evidence for Mycobacterium leprae Drug Resistance in a Large Cohort of Leprous Neuropathy Patients from India. 61
31933458 2020
Myelin breakdown favours Mycobacterium leprae survival in Schwann cells. 61
31652371 2020
Commingled crypts: Comparative health among Byzantine monastics in the Levant. 61
31907930 2020
FAMIN Is a Multifunctional Purine Enzyme Enabling the Purine Nucleotide Cycle. 61
31978345 2020
Human Genetic Susceptibility of Leprosy Recurrence. 61
31992776 2020
Leprosy in skulls from the Paris Catacombs. 61
31989850 2020
Cytokine Levels in Neural Pain in Leprosy. 61
32038662 2020
Lucio Phenomenon: Sequelae of Neglected Leprosy. 61
31968408 2020
Frequent testicular involvement in multibacillary leprosy. 61
31634613 2020
Reply to: Single-dose rifampicin and BCG to prevent leprosy. 61
32014601 2020
Single-dose rifampicin and BCG to prevent leprosy. 61
32014603 2020
Prevention of transmission of leprosy: The current scenario. 61
31975697 2020
18F-FDG PET/CT Imaging Findings of Leprosy. 61
31977489 2020
Tuberculoid leprosy: An in vivo microvascular evaluation of cutaneous lesions. 61
31929590 2020
Leprosy elimination - Still a long way to go. 61
31939491 2020
Leprosy pseudoimbricata: an unusual presentation of steroid-modified borderline lepromatous leprosy. 61
31957882 2020
Schwann cells as underestimated, major players in human skin physiology and pathology. 61
31733169 2020
Indian Sarsaparilla (Hemidesmus indicus): Recent progress in research on ethnobotany, phytochemistry and pharmacology. 61
32007632 2020
A critical comparative ethnographic study of courtesy stigma in two leprosy-impacted communities in Indonesia. 61
31971879 2020
Leprosy in French Guiana 2007-2014: a re-emerging public health problem. 61
31286485 2020
Type 2 leprosy reaction resembling Sweet syndrome: Review of new and published cases. 61
31984474 2020
Utility and limitations of serodiagnostic tests in monitoring the response to treatment of leprosy patients. 61
31954594 2020

Variations for Leprosy 3

ClinVar genetic disease variations for Leprosy 3:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TLR2 NM_003264.5(TLR2):c.2029C>T (p.Arg677Trp)SNV risk factor 6663 rs121917864 4:154626088-154626088 4:153704936-153704936

Copy number variations for Leprosy 3 from CNVD:

# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 255081 9 72339785 73251640 Duplication TRPM3 Leprosy

Expression for Leprosy 3

Search GEO for disease gene expression data for Leprosy 3.

Pathways for Leprosy 3

Pathways related to Leprosy 3 according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.61 TNF IL2 IL10 IFNG CD40LG CD4
Show member pathways
12.56 TNF IL2 IL10 IFNG CD4
Show member pathways
8 12.52 TNF TLR2 IL2 IL10 IFNG CD8A
Show member pathways
Show member pathways
12.29 TNF IL2 IL10 CCR6
Show member pathways
12.29 TLR2 SLC11A1 CD4 CCR6
Show member pathways
13 12.19 TNF TLR2 NOD2 IL10 IFNG
Show member pathways
Show member pathways
11.96 IL2 IFNG CD8A CD4
16 11.89 TNF TLR2 IL10 IFNG
17 11.86 TNF IL2 IL10 IFNG CD8A CD4
Show member pathways
19 11.7 TNF IL2 IL10 IFNG
Show member pathways
Show member pathways
22 11.55 IL10 CD40LG CD4
23 11.53 TNF IL2 IFNG
24 11.5 TNF TLR2 IFNG
25 11.49 TNF IL2 IFNG
26 11.47 TNF TLR2 IL10 IFNG CD40LG
27 11.46 IL2 IL10 IFNG CD4
28 11.38 CD8A CD40LG CD4
29 11.36 TNF IL10 IFNG
30 11.31 IL2 IFNG CD40LG
31 11.3 TNF IL2 IL10 IFNG CD8A CD4
32 11.22 IL2 IFNG CD4
33 11.18 IL2 IL10 IFNG
34 11.07 TNF IL2 IL10 IFNG CD8A CD4
35 11.02 TNF IL2 IL10 IFNG CD4

GO Terms for Leprosy 3

Cellular components related to Leprosy 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.46 TNF TLR2 LRRK2 CD4
2 external side of plasma membrane GO:0009897 9.35 TNF CD8A CD40LG CD4 CCR6
3 cell surface GO:0009986 9.1 TNF TLR2 NOD2 CD40LG CD4 CCR6

Biological processes related to Leprosy 3 according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 TNF TLR2 SLC11A1 PRKN NOD2 IL2
2 positive regulation of gene expression GO:0010628 10.05 TNF TLR2 SLC11A1 PRKN IFNG
3 inflammatory response GO:0006954 9.98 TNF TLR2 SLC11A1 IL10 CD40LG
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.89 TNF PRKN NOD2 CD4
5 negative regulation of protein phosphorylation GO:0001933 9.85 PRKN LRRK2 IL2
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 TNF TLR2 NOD2 CD40LG
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 TNF IL2 IFNG
8 cellular response to organic cyclic compound GO:0071407 9.82 TNF NOD2 LRRK2
9 positive regulation of MAP kinase activity GO:0043406 9.81 TNF NOD2 LRRK2
10 positive regulation of T cell proliferation GO:0042102 9.8 IL2 CD40LG CD4
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 TNF TLR2 NOD2
12 positive regulation of interleukin-6 production GO:0032755 9.79 TNF TLR2 NOD2
13 humoral immune response GO:0006959 9.77 TNF IFNG CCR6
14 positive regulation of phagocytosis GO:0050766 9.73 TNF SLC11A1 IFNG
15 positive regulation of interferon-gamma production GO:0032729 9.72 TNF SLC11A1 IL2
16 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF IFNG
17 negative regulation of amyloid-beta clearance GO:1900222 9.67 TNF IFNG
18 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL10 IFNG
19 positive regulation of programmed cell death GO:0043068 9.66 TNF LRRK2
20 cellular response to manganese ion GO:0071287 9.65 PRKN LRRK2
21 endothelial cell apoptotic process GO:0072577 9.64 TNF IL10
22 microglial cell activation GO:0001774 9.63 TNF TLR2 IFNG
23 protein localization to mitochondrion GO:0070585 9.61 PRKN LRRK2
24 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.61 SLC11A1 NOD2
25 positive regulation of interleukin-8 production GO:0032757 9.61 TNF TLR2 NOD2
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 TNF IL10
27 positive regulation of interleukin-12 production GO:0032735 9.58 TLR2 IFNG CD40LG
28 regulation of immunoglobulin secretion GO:0051023 9.57 TNF CD40LG
29 positive regulation of protein phosphorylation GO:0001934 9.55 TNF LRRK2 IL2 IFNG CD4
30 cytokine secretion involved in immune response GO:0002374 9.52 TLR2 NOD2
31 regulation of synaptic vesicle transport GO:1902803 9.51 PRKN LRRK2
32 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 TNF IFNG
33 receptor biosynthetic process GO:0032800 9.48 TNF IL10
34 positive regulation of interleukin-10 production GO:0032733 9.43 TLR2 NOD2 CD40LG
35 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 TNF IFNG
36 positive regulation of nitrogen compound metabolic process GO:0051173 9.32 TNF IFNG
37 immune response GO:0006955 9.32 TNF TLR2 SLC11A1 IL2 IL10 IFNG
38 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.26 TLR2 NOD2 LRRK2 IFNG

Molecular functions related to Leprosy 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Hsp70 protein binding GO:0030544 9.13 PRKN PACRG NOD2
2 cytokine activity GO:0005125 9.02 TNF IL2 IL10 IFNG CD40LG

Sources for Leprosy 3

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....